Sanofi SG&A Expense: 3.06B
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
None selected
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
SNY SG&A Expense Rankings
| Overall | 1st percentile | 4334 of 4399 |
| Sector | 0th percentile | 503 of 508 in Healthcare |
| Industry | 18th percentile | 22 of 27 in Drug Manufacturers - Major |
SNY SG&A Expense Range, Past 5 Years
| Minimum | 2.46B | Jun 2005 |
| Maximum | 3.01B | Dec 2005 |
| Average | 2.61B |
About SG&A Expense
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
The details of how SG&A expenses are calculated vary widely from company to company, so YCharts recommends looking at the annual report (10-k) an investor is interested in dissecting this number further.
Learn More
You may also be interested in these SNY related companies
SNY News
Sanofi's (SNY) Genzyme Reports Continued Endpoint Improvement for Eliglustat Tartrate in Phase 2 Trials
Feb 08, 11:04AM Street Insider
Feb 08, 11:04AM Street Insider
Sanofi (SNY), Bristol-Myers Squibb (BMY) Get $442.2M Payment from Plavix Settlement
Feb 08, 6:52AM Street Insider
Feb 08, 6:52AM Street Insider
Sanofi and Bristol-Myers Squibb Collect Damages in Plavix Patent Litigation with Apotex
Feb 08, 1:30AM Business Wire
Feb 08, 1:30AM Business Wire
Sanofi Announces FDA Approval of Sklice® Lotion for the Treatment of Head Lice
Feb 07, 2:05PM Benzinga
Feb 07, 2:05PM Benzinga
A Forward Look, the Year Ahead - Featured Research on Sanofi SA (ADR) and Endo Pharmaceuticals
Feb 06, 9:00AM Marketwire
Feb 06, 9:00AM Marketwire
R&D in Quebec pharma industry continues to erode $AZN $JNJ $SNY $MRK
about 10 days ago by michaelbabad
about 10 days ago by michaelbabad
$SNY informs $REGN of voluntary withdrawl of Zaltrap BLA based on FDA comments. Plans to resubmit in early 2012 http://stks.co/1eBM
about 53 days ago by TradeHawk
about 53 days ago by TradeHawk
Looking for Euro denominated share ADRs with large US revenues. e.g., $SNY, $SI. Suggestions?
about 59 days ago by paladinmoney
about 59 days ago by paladinmoney
I have to say, it really is ironic that $SNY has one of the lowest valuations in big-pharma when it has the best management by far.
about 63 days ago by bradloncar
about 63 days ago by bradloncar
Business Insider - Barron's: Here Are The Top 10 Stocks For 2012 $BRKA $MET $SNY $STX $FCX $CMCSA $RDSA $PG http://stks.co/1TzI > buy puts?
about 64 days ago by OptionsCommander
about 64 days ago by OptionsCommander
I detail everything that goes into my Risk/Reward scoring system in my book, Better Good than Lucky. http://stks.co/1Tqp $RDS.A $SNY $VOD
about 64 days ago by charlesrotblut
about 64 days ago by charlesrotblut
Barron's 2012 favorite stocks with strong Risk/Reward scores are $RDS.A, $SNY & $VOD This does not make them buys; do your own research.
about 64 days ago by charlesrotblut
about 64 days ago by charlesrotblut
$GME ready for the Santa Claus rally thanks to Call of Duty: MW3 and shorts. $NVDA $MSFT $ATVI $TTWO $ERTS $SNY $SODA http://stks.co/1CgL
about 85 days ago by Vinnystocktips
about 85 days ago by Vinnystocktips
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| SNY | 37.23 | -0.18 | -0.48% | 97.62B |
| WFT | 17.79 | -0.41 | -2.25% | 13.33B |
| KFT | 38.58 | -0.06 | -0.16% | 68.14B |
| C | 32.92 | -0.73 | -2.18% | 96.26B |
| SGI | 9.89 | -0.41 | -3.93% | 312.33M |
| AMAT | 12.95 | -0.16 | -1.22% | 17.06B |
| FRP | 4.42 | -0.43 | -8.87% | |
| LNG | 13.93 | -0.34 | -2.38% | 1.15B |
| ABR | 4.54 | -0.05 | -1.09% | 115.50M |
| NDN | 22.01 | 0.02 | 0.09% | 1.55B |
